Bioventus (BVS) Receivables (2020 - 2026)

Bioventus' Receivables history runs 7 years deep, the most recent figure standing at $123.6 million for Q1 2026.

• Quarterly Receivables rose 2.21% year-over-year to $123.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.6 million (up 2.21% YoY) and the FY2025 annual result came in at $128.5 million, up 0.79% from the prior year.
• Receivables was $123.6 million for Q1 2026 at Bioventus, down from $128.5 million in the prior quarter.
• Across five years, Receivables topped out at $148.3 million in Q3 2022 and bottomed at $117.9 million in Q3 2023.
• A 5-year average of $128.8 million and a median of $128.5 million in 2025 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables surged 45.36% — and 2023, when it declined 19.33%.
• Bioventus' Receivables stood at $136.6 million in 2022, then dropped by 6.86% to $127.3 million in 2023, then grew by 0.16% to $127.5 million in 2024, then grew by 0.79% to $128.5 million in 2025, then declined by 3.81% to $123.6 million in 2026.
• Business Quant data shows BVS's Receivables at $123.6 million in Q1 2026, $128.5 million in Q4 2025, and $130.4 million in Q3 2025.